NCT00048087View on ClinicalTrials.gov

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2002

Primary Completion Date

July 31, 2003

Study Completion Date

July 31, 2003

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

ZD1839

250 mg by mouth daily each day for 4 weeks.

DRUG

Docetaxel

30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER